Carboplatin

For research use only.

Catalog No.S1215 Synonyms: JM-8, CBDCA, NSC 241240

44 publications

Carboplatin Chemical Structure

Molecular Weight(MW): 371.25

Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Size Price Stock Quantity  
USD 77 In stock
USD 107 In stock
USD 167 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Carboplatin has been cited by 44 publications

Purity & Quality Control

Choose Selective Antineoplastic and Immunosuppressive Antibiotics Inhibitors

Biological Activity

Description Carboplatin is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.
Features This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).[6]
Targets
DNA synthesis [1]
(A2780, SKOV-3, IGROV-1, HX62 cells)
In vitro

Carboplatin exhibits an inhibitory effect on cell proliferation in a human ovarian cancer cell line panel, including A2780, SKOV3, and IGROV-1 cells with IC50 of 6.1 μM, 12.4 μM and 2.2 μM, respectively. [1] Carboplatin also show the anti-proliferative activities in lung carcinoid cell line, such as UMC-11, H727, and H835 cells with IC50 of 36.4 μM, 3.4 μM and 35.8 μM, respectively. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Tca8113/ut  MnW1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPkNk0zPeLCid88US=> NITxOII4OiCq MoK4bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? MoHjNlYyOzdzMEW=
Tca8113/CBP  M{TOemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXWyMVI26oDLzszN MUK3NkBp NFHoN3dqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NUHVSnFzOjZzM{exNFU>
Tca8113/PYM  MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\pbpAzOi1{NfMAje69VQ>? MmrHO|IhcA>? MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NHfPWW0zPjF|N{GwOS=>
SKOV3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\WUo83OCCvZz;tcC=> MYSxMVUh\A>? MY\pcohq[mm2czDj[YxtKH[rYXLpcIl1gSC2aX3lJIRmeGWwZHXueIx6 M1X5XFI3OTN5MESz
SKOV3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ftUVAuPCEQvHevcYw> M3SxblI1NzR6L{eyJIg> M1fTfIlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51dHl? MojaNlYyOjV{N{O=
SKOV3 NHziZmJCeG:ydH;zbZMhSXO|YYm= NYjBemJDOiEQvHevcYw> M2DjPVQ5KGh? NUS5VWRIcW6mdXPld{BieG:ydH;zbZM> MWSyOlEzPTJ5Mx?=
OSA M1fvb2Ntd26xZ3XubYMhSXO|YYm= NI\MSpIzNjVxNTFOwG0> NUPvUGdRemW|dXz0d{BqdiCub4fldkBkd2yxbomg[o9zdWG2aX;uJIF{KGOxbYDhdoVlKHSxIHXpeIhmeiCETVmxJJNqWk6DIITy[YF1dWWwdB?= NUXTWGNROjZzMUC2NlA>
A549 NG\sV4lHfWO2aX;uJGF{e2G7 NEPheGsxNzJ3L{WwJO69VQ>? MorMNlQhcA>? MorG[I94dnKnZ4XsZZRmeyCvaWKtNlA2KGW6cILld5Nqd28EoB?= MlnCNlU6OTd|MUe=
H1975 NGn2NIdHfWO2aX;uJGF{e2G7 NH3Ge2UxNzJ3L{WwJO69VQ>? NX:z[IJlOjRiaB?= M{nDd4Rwf26{ZXf1cIF1\XNibXnSMVIxPSCneIDy[ZN{cW:wwrC= M{H1OFI2QTF5M{G3
A549 NWHTVZBFTnWldHnvckBCe3OjeR?= MWCwM|I2NzVyIN88US=> M3;qS|I1KGh? Moq0eZBz\We3bHH0[ZMhdWmULUKxPEBmgHC{ZYPzbY9v MWCyOVkyPzNzNx?=
H1975 MWLGeYN1cW:wIFHzd4F6 M1f6WFAwOjVxNUCg{txO Ml65NlQhcA>? Ml3seZBz\We3bHH0[ZMhdWmULUKxPEBmgHC{ZYPzbY9v NH\BOoIzPTlzN{OxOy=>
A549 M1Hrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;pcVI2KM7:TR?= NYLSVoR[OjRiaB?= NVzNb3RNcW6qaXLpeJMh[2WubDDndo94fGh? MVeyOVkyPzNzNx?=
H1975 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHlNlUh|ryP MoD6NlQhcA>? NX3jd2RbcW6qaXLpeJMh[2WubDDndo94fGh? MmTUNlU6OTd|MUe=
MDA-MB-231 Ml\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1vyN|AuOjJyIN88[{9udA>? NE\Ie4o4OiCq MXnJR|UxyqB;IEi2JO69VQ>? MnLONlU5Ozd4OUG=
T47D NVzWSZdbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{WzXVAuOjJyIN88[{9udA>? NEfneVQ4OiCq NULl[oNkUUN3MNMgQUA1QC57IN88US=> M1\lVlI2QDN5Nkmx
LCTCC NWXKZm1lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITtV5ZKSzVyPUOuPQKBkcL3TR?= M4PpcVI2Pzd|MU[3
MCTCC NUDPT2p6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDZW3RWUUN3ME2yMljjiIoEtV2= M1riNFI2Pzd|MU[3
MegTCC NYLndlZqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\CRpIxUUN3ME20MlHjiIoEtV2= M3fpdFI2Pzd|MU[3
MonoTCC NUnUbWhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXHld5h3UUN3ME21MlbjiIoEtV2= NHXYTlEzPTd5M{G2Oy=>
MCF7 M1HvOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGP3TngzOCEQvF2= MoHTO|IhcA>? MWPpcoR2[2W|IHPlcIwh\GWjdHigc4YhUFBzzsKt[IVxdGW2ZXSgUWNHPyClZXzsdy=> MmXwNlU4PjlyMkW=
A-549  MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPrR5gxNjVizszN MkHJNlQhcA>? NYLnepUyTE2VT9Mg MWPpcohq[mm2czDj[YxtKGe{b4f0bEB{cWewaX\pZ4FvfGy7 MlnpNlU4PTV4OUC=
A-549  MULBdI9xfG:|aYOgRZN{[Xl? MnTJNE42KM7:TR?= NYrMXW1zPDhiaB?= M1zzeWROW00EoB?= M1;YXJNpd3e|IHXhdox6KGGyb4D0c5NqeyCoZXH0eZJmeyCrbnPseYRqdmdiYnzlZoJqdmdiYX7kJINpem:vYYTpckBkd26mZX7zZZRqd25? NX\Ie2J[OjV5NUW2PVA>
A-549  NIPC[FVHfWO2aX;uJGF{e2G7 NFXrfGQxNjVizszN MWm0PEBp MUXEUXNQyqB? NIW3R3Z{cG:5czDhZoVzemGwdDDtbYNzd3S3YoXs[UBlcXO{dYD0bY9v NGjkdoozPTd3NU[5NC=>
A-549  NYS4b3loTnWldHnvckBCe3OjeR?= NWjpfZR[OC53IN88US=> NVHJTHZGPDhiaB?= NYfJXWRPTE2VT9Mg NXPTPZl4cW6qaXLpeJMhd2ZiY3XscEBucWe{YYTpc47DqA>? NFnJVGczPTd3NU[5NC=>
RMG-1 NU\kTJhmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ6LkigxtEhOy54IH3nM2w> NFPmPZAzPTd{NkmxNy=>
FN-RMG-1 NIq2WXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTRyLkWgxtEhPC5{IH3nM2wLKM7:TR?= MkXoNlU4OjZ7MUO=
RMG-1-hFUT NVXnSm1zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MofLTWM2OD13OD6xJOKyKDJwNDDt[{9N NHfiW4czPTd{NkmxNy=>
FN-RMG-1-hFUT NWHBXYdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DsN2lEPTB;MUG4MlghyrFiMUOuPEBu\y:O NWHJeVI1OjV5Mk[5NVM>
CHP-134  MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTpNUDPxE1? MVLEUXNQyqB? NU\nN5g2cW6qaXLpeJMhe2mpbnnmbYNidnRiY3XscEBoem:5dHigZ49u[mmwZXSge4l1cCCJU1uyPFMxOzdz M3G2OFI2PjV6NE[z
IMR-32 NXHOd3o5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkLONUDPxE1? NGPPSGlFVVORwrC= MUnpcohq[mm2czDzbYdvcW[rY3HueEBk\WyuIHfyc5d1cCClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> MWmyOVY2QDR4Mx?=
CHP-134  Mo\QSpVkfGmxbjDBd5NigQ>? M1u0e|ExKM7:TdMg MYXEUXNQyqB? MVfpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigS3NMOjh|MEO3NS=> NHLsfHIzPTZ3OES2Ny=>
IMR-32 NIXycpdHfWO2aX;uJGF{e2G7 MlnXNVAh|ryPwrC= MVjEUXNQyqB? MlnZbY5lfWOnczDhdI9xfG:|aYOgd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJGdUUzJ6M{CzO|E> MXWyOVY2QDR4Mx?=
A549 M{f0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7qNE4zNTRyMECg{txO MXu3NkBp MlezTWM2OD1zMk[gxtEhPS5yIN88US=> MkH5NlU3OjV{NEO=
A549/CDDP MmHaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfzWY53OC5{LUSwNFAh|ryP MoXkO|IhcA>? NX;3bZI6UUN3ME2yOFDDqMLzwrC0OU44KM7:TR?= M1vjeFI2PjJ3MkSz
H460  NEjxZ4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfqeIszPCCq M1LGNGROW09? NWT4VZZ3UUN3ME23Mlkh|ryP MXeyOVU6QTl7NR?=
H460  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zXWVcvQSEQvF2= MVmyOEBp M2Pl[mROW09? M{O5S5Npd3e|IHGgdoFlcW:|ZX7zbZRqgmmwZzDl[oZm[3RidH:gXE1z[Xm| M1H3T|I2PTl7OUm1
NRK-52E NILvUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWq3NuKhcMLi M2LyOmlEPTB;MUCwJOKyKDF{Lkmg{txO MU[yOVU3PTZyMx?=
RGE MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1zzeVczyqCqwrC= MorRTWM2OD1{MjFCtUA4NjRizszN M{LveFI2PTZ3NkCz
NRK-52E M3X4V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M37F[lczyqCqwrC= NFL4dpdKSzhyPUG3PUDDuSB7LkWg{txO MofWNlU2PjV4MEO=
RGE MmjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPudoM4OsLiaNMg NUjrOJlxUUN6ME22N{DDuSB5LkSg{txO Ml36NlU2PjV4MEO=
SK-OV-3 NFPH[G5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn30O|IhcA>? M4fGVGlEPTB;MUC0Mlgh|ryP MX2yOVUzODF|Mh?=
ES-2 NIjRfnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFz2[mc4OiCq NV3WR|JGUUN3ME2xOE43KM7:TR?= MUiyOVUzODF|Mh?=
OVCAR-8 NHr4c2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFP1T2E4OiCq NF7lOlBKSzVyPUm2MlAh|ryP MmPKNlU2OjBzM{K=
3AO MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVW3NkBp NIHHSVBKSzVyPU[zMlQh|ryP NW\XfVc4OjV3MkCxN|I>
A2780 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSwO|IhcA>? NF;WT4JKSzVyPUG0OU44KM7:TR?= M3f5eVI2PTJyMUOy
SW626 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjtWGQ4OiCq M2\zemlEPTB;OUeuNEDPxE1? MUCyOVUzODF|Mh?=
OVCAR-3 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWG3NkBp NH\DZXhKSzVyPUOyMlYh|ryP MX6yOVUzODF|Mh?=
A549 NUPUeJM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LpPGlEPTB;MUWxMlU3KMLzIEWzMlA3KM7:TR?= NXTWR5JOOjV{N{e0OlE>
4T1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUftXIF3UUN3ME24OE43OiEEsTCzNE4xPSEQvF2KJO69VQ>? MWSyOVI4PzR4MR?=
BALB/3T3 NIXaXFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXHqVXB{UUN3ME2xOE4{OCEEsTC2MlY5KM7:TR?= NYPYfYpsOjV{N{e0OlE>
B16 Mn73S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3LK[2lEPTB;NkSuN|AhyrFiNj64NUDPxE1? NE\m[3EzPTJ5N{S2NS=>
DU 145 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zvZWlEPTB;M{WuNFQhyrFiMUeuOVQh|ryP NH7rXHQzPTJ5N{S2NS=>
FaDu MlLYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTR3LkO5JOKyKDFzLkWwJO69VQ>? MYWyOVI4PzR4MR?=
HCV-29T M4nCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTR6LkW3JOKyKDJ{LkS5JO69VQ>? NXzoW41EOjV{N{e0OlE>
HL-60 NXPGb4dQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFjTXlNKSzVyPUGxMlExKMLzIESuOFch|ryP M1;SN|I2Ojd5NE[x
HT-29 MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTh7LkG2JOKyKDF6Lki2JO69VQ>? NV3tdoR6OjV{N{e0OlE>
H146 NGTTc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv3[HE5UUN3ME20PU43yrFzMz6xJO69VQ>? MkjCNlUyOjR{OEK=
H187 M2jiVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2LZWWlEPTB;MUKuO:KyOi55IN88US=> MV[yOVEzPDJ6Mh?=
H128 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIruPW9KSzVyPUGwOk41yrF7Lk[g{txO NHzCOmczPTF{NEK4Ni=>
H69 M{LDTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mle4TWM2OD15Nj65xtEzPy56IN88US=> NIHUNFEzPTF{NEK4Ni=>
H209 NFfUe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDGTWM2OD1{NUiuNeKyQTlwODFOwG0> NETSVXczPTF{NEK4Ni=>
DMS153 MlXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfRPFlKSzVyPUW3MljDuTlwMjFOwG0> NF7nWIczPTF{NEK4Ni=>
H526 NISyN|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP4TWM2OD15LkNCtVEvPyEQvF2= NYnZVHZSOjVzMkSyPFI>
DMS114 MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIC5fXRKSzVyPUi1MljDuTF{Lkig{txO MXqyOVEzPDJ6Mh?=
DMS53 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTF2Nj6yxtE{Pi52IN88US=> MYSyOVEzPDJ6Mh?=
HeLa M2XhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4OxelUuQDBizszN NYPUXGo2cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? NUDqd5hyOjVzMEmzOlA>
MCF-7 M333UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3XOU05OCEQvF2= MV3pcohq[mm2czDj[YxtKGe{b4f0bEBld3OnIHTldIVv\GWwdHz5 NXXjfVE6OjVzMEmzOlA>
MDA-MB-231 MknLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;iOU05OCEQvF2= M4fmcYlvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> NFrIWGMzPTFyOUO2NC=>
CaOV3 M4KzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXm3NkBp NULpUW1bUUN3ME24Ok4yKM7:TR?= MWSyOVA3QDh2OR?=
OVCAR-3 NIrQUmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY[xV2w2PzJiaB?= NV7JdoR6UUN3ME2xO|kvPSEQvF2= NEnzdIczPTB4OEi0PS=>
OVCAR-5 NW\oRnNpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC3NkBp M3e0RmlEPTB;N{WuO{DPxE1? M1nyS|I2ODZ6OES5
SKOV-3 MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme2O|IhcA>? NFLuPXFKSzVyPUWwOEDPxE1? NHq5SI4zPTB4OEi0PS=>
OVCAR-4 Ml;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPneo9NPzJiaB?= MnvuTWM2OD1{OUCuOkDPxE1? M4jFNlI2ODZ6OES5
OVCAR-8 NFTTNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\WO|czKGh? M2\DUmlEPTB;NkmwMlIh|ryP M2fuflI2ODZ6OES5
MA148 MnTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XlXVI1KGh? MWLJR|UxRTh|LkdihKnDueLCiUGuOEDPxGdxbXy= M2TZcFI1QDNzMEmx
A549 NULheJpKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFe4eFQzPCCq M4LHSWlEPTB;N{e2MlDjiIoEsfMAjVEvQSEQvHevcYw> NX;Ed4xMOjR6M{GwPVE>
MDA-MB-231 NWLVb25LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO2NmIzPCCq NWTxWGk2UUN3ME23OFgvOOLCidMx5qCKOS5zIN88[{9udA>? NWrQfGJyOjR6M{GwPVE>
NCI-ADR/RES  MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfadZozPCCq NXHJcYkxUUN3ME2xO|U{NjEkgJpCtgKBkTRwNDFOwIcwdWx? NYXtcYQzOjR6M{GwPVE>
MA148 NIfnXm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFy2fI01QCCq NInCZ|NKSzVyPUK4MlHjiIoEsfMAjVEvOCEQvHevcYw> M1i0N|I1QDNzMEmx
A549 NXzBeGR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzubHV5PDhiaB?= MoCxTWM2OD1zMUiuNQKBkcLz4pEJNU4zKM7:Zz;tcC=> M3PqfFI1QDNzMEmx
MDA-MB-231 M2fIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\F[IU1QCCq M2TzfmlEPTB;MUizMlDjiIoEsfMAjVEvOiBizsznM41t M{jZUVI1QDNzMEmx
NCI-ADR/RES  NHPMbJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{T4[lQ5KGh? NXXpNItZUUN3ME2xPVMvOOLCidMx5qCKOS57IN88[{9udA>? NUO3b5kxOjR6M{GwPVE>
MA148 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;r[2NQPzJiaB?= NGCwTllKSzVyPUGzMlfjiIoEsfMAjVEvOiEQvHevcYw> M2i1R|I1QDNzMEmx
A549 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLaO|IhcA>? MVvJR|UxRTZ2LkRihKnDueLCiUGuNUDPxGdxbXy= NU\NRYoyOjR6M{GwPVE>
MDA-MB-231 NILZWXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTKenY4OiCq NGDUOpJKSzVyPUm5MlXjiIoEsfMAjVEvOSEQvHevcYw> NGPPT20zPDh|MUC5NS=>
NCI-ADR/RES  M3TaTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSyO|IhcA>? MnTXTWM2OD1|Nz605qCKyrIkgJmxMlch|rypL33s NXHXdZl3OjR6M{GwPVE>
A549 M170bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoO4O|IhcA>? Mm\sSG1UVw>? MVfJR|UxRTF3Mj60NFkh|ryP MW[yOFczOTN{Mx?=
NCI-H157 NIjTUYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmq3O|IhcA>? MX;EUXNQ Moj4TWM2OD16OT65O|ch|ryP MVeyOFczOTN{Mx?=
PC9 Mm\jS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXe3NkBp M1u0[GdEPTB;N{GuOuKyQS53INM1US=> NUHqbVhLOjR4MUi4NFk>
A549  M2jkZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jGUVczKGh? MYHHR|UxRTF|NtMxN|EvPiEEtV5CpC=> NYfuPWZ[OjR4MUi4NFk>
PC9 NInCZ2pCeG:ydH;zbZMhSXO|YYm= NXzGSlRxOTByINM1US=> NG\yVGU4OiCq MVXpcoR2[2W|IHHwc5B1d3Orcx?= MnfWNlQ3OTh6MEm=
A549  MYLBdI9xfG:|aYOgRZN{[Xl? MY[xNFAhyrWP M1jmSVczKGh? NH\YbXRqdmS3Y3XzJIFxd3C2b4Ppdy=> MYeyOFYyQDhyOR?=
A549 NGqycYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUmyOEBp M1zlXWlEOTB;MT60O|Yhdk1? MUiyOFM6PjR|Nx?=
H1299 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NET4e2gzPCCq NHXsXZhKSzFyPUCuOFQ{KG6P MW[yOFM6PjR|Nx?=
HCC15 NG\0RpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWGyOEBp NXPoSm9kUUNzME2wMlM1PiCwTR?= MYmyOFM6PjR|Nx?=
H157 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInPc|UzPCCq M37afmlEOTB;MD64NUBvVQ>? MlKwNlQ{QTZ2M{e=
A2780 NYfOSW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjLS5JyUUN3ME2xOE4x6oDLwsJihKkyNjRizszN M4LVOVI1OjB7Nkmz
A2780cisR MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGP0TlhKSzVyPUS4MlnjiIoEsfMAjVMvQSEQvF2= MYiyOFIxQTZ7Mx?=
A2780ZD0473R M{jQVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmnmTWM2OD14ND625qCKyrIkgJmzMlIh|ryP NH7pUIszPDJyOU[5Ny=>
SKOV-3 NEi4WlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLyblJDUUN3ME20N{416oDLwsJihKk{NjlizszN MXyyOFIxQTZ7Mx?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pChK-2 / Chk-2 ; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated Chk-2. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p53(S15) / p-p53(S46) / p-p53(S392) / p53; 

PubMed: 30049957     


Validation of the kinase array data by Western blotting. A2780s and A2780cp cells were left untreated or treated with 50 μM carboplatin for 24 h, and the whole cell lysates were collected for Western blotting to measure total and phosphorylated p-p53. β-a䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ

p-p38 / p38 / Cleaved PARP / PARP ; 

PubMed: 30049957     


A2780s and A2780cp cells were treated with increasing concentrations of carboplatin for 48 h. Phosphorylation of p38 and cleavage of Poly(ADP-ribose) polymerase (PARP) were analyzed by Western blotting. Two antibodies were used to examine the cleaved PARP䲧疝Ỵ疞㧀疜膉痘 瘿뙠ෆᾰƌෆĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ෆĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ�෋䐺痖暼瘿�෋ᾰƌ �෋Ð㺣痖�෋€𢡄�෋€䀷痗�෋౴�෋㵶痗�෋뺖᎒泌Itemセ᎒Count﫨呂�෋猴፲�෋፲씢痗猸፲髸莤䥷堙᎒セ᎒�堞ﻮ᎒፲露𢡄

30049957
Immunofluorescence
γH2AX ; 

PubMed: 24348048     


Carboplatin induced DNA damage in SiHa cells. SiHa cells were exposed to 20, 40, and 80 μmol/L carboplatin for 12 hours, respectively. Immunofluorescence analysis was used to detect nuclear γ-H2AX foci formation with anti-H2AX antibody (red, fluorescein i䲧疝Ỵ疞㧀疜膉痘 瘿삨ՂᾰƌՂĀ 㺣痖帉痖Ѐ

24348048
Growth inhibition assay
Cell viability ; 

PubMed: 24348048     


SiHa and CaSki cells were treated with the indicated concentrations of carboplatin for 72 hours, and cell viability was measured by Cell Counting Kit-8 viability assay. 

24348048
In vivo

In A2780 tumor xenografts, Carboplatin (60 mg/kg via i.p.) given as single agents shows a modest antitumor effect with the relative tumor volumes on day 6 of 8.4 compared to the control of 11.9, and the day 6 tumor weights relative to control (T/C) of 67%. [1] For the VC8 (Brca2-deficient) xenografts, Carboplatin treatment delays tumor growth and reduces tumor mass by 42% compared to the vehicle group. [3]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: A2780, SKOV3, IGROV-1 and HX62
  • Concentrations: 0-200 μM
  • Incubation Time: 72 hours
  • Method:

    3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assays: Exponentially growing A2780, SKOV3, IGROV-1 and HX62 ovarian cancer cells are plated in 96 well plates. A range of drug concentrations are added and the plates are incubated for 72 hours to allow for 3–4 doubling times. Each experiment is carried out in triplicate. Sulforhodamine B (SRB) assays: Exponentially growing A2780 cells are plated in 96 well microtitre plates. For experiments studying concomitant exposure, cells are exposed to increasing concentrations of both drugs for 96 hours. For experiments studying the effect of sequence of exposure to 17-AAG or carboplatin cells are exposed to increasing concentrations of 17-AAG or carboplatin for 24 hours. A period of 24-hour exposure to the first agent is chosen so that the A2780 cells would be exposed to the first drug for at least one doubling time (18-24 hours). The cells are then washed with sterile phosphate buffered saline and the medium is replenished. Following this, the second drug (to which the cells are not exposed to in the first 24 hours) or medium is added for 96 hours. All experiments are carried out in triplicate. The results of combination studies are analyzed using the well-established principles of median effect analysis method. The effects of the combination are calculated using an in-house spreadsheet.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: The A2780 human ovarian cancer cell line is grown as a subcutaneous xenograft in female athymic NCr nude mice (nu/nu) in each flank.
  • Dosages: ≤60 mg/kg (When Carboplatin is dissolved in sodium chloride solution, it will induce physio-chemical and pharmacokinetic changes.)
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro Water 14 mg/mL warmed (37.71 mM)
DMSO Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 371.25
Formula

C6H12N2O4Pt

CAS No. 41575-94-4
Storage 2 years 4°C(in the dark) powder
1 week 4°C(in the dark) in solvent
Synonyms JM-8, CBDCA, NSC 241240
Smiles N.N.[Pt++].[O-]C(=O)C1(CCC1)C([O-])=O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04354961 Not yet recruiting Drug: Almonertinib|Drug: Paclitaxel and carboplatin Pulmonary Adenosquamous Carcinoma Fujian Cancer Hospital|Jiangsu Hansoh Pharmaceutical Co. Ltd. June 2020 Phase 2
NCT04222426 Recruiting Other: 89Zr-atezolizumab PET scans Lobular Metastatic Breast Cancer University Medical Center Groningen December 18 2019 Not Applicable
NCT04163094 Recruiting Drug: W_ova1 Vaccine Ovarian Cancer University Medical Center Groningen|Biontech RNA Pharmaceuticals GmbH November 25 2019 Phase 1
NCT04125446 Recruiting -- Cancer|Pregnancy University Hospital Gasthuisberg October 15 2019 --
NCT03968653 Recruiting Drug: Debio 0123|Drug: Carboplatin Advanced Solid Tumors Debiopharm International SA July 30 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Can you advise what solvent to use and the concentration for S1215 for in vitro use?

  • Answer:

    DMSO will affact the activity of platinum agents. For in vitro use, according to our experience in dissolving this compound, we didn't find any solvent can dissolve it alone, but S1215 can be dissolved in co-solvent ethanol:water=1:2 at 15 mg/ml. We didn't test the stablility of the drug in such vehicle, so it is recommended to prepare the solution just before use.

Tags: buy Carboplatin | Carboplatin supplier | purchase Carboplatin | Carboplatin cost | Carboplatin manufacturer | order Carboplatin | Carboplatin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID